It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer?
None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.
By creating a method to spot the drivers in a sea of passengers, scientists at the Broad Institute of MIT and Harvard, the Dana-Farber Cancer Institute and The University of Texas MD Anderson Cancer Center have identified six genes with driving mutations in melanoma, three of which have recurrent 'hotspot' mutations as a result of damage inflicted by UV light. Their findings are reported in the July 20 issue of the journal Cell.
"Those three mutations are the first 'smoking gun' genomic evidence directly linking damage from UV light to melanoma," said co-senior author Lynda Chin, M.D., Professor and Chair of MD Anderson's Department of Genomic Medicine. "Until now, that link has been based on epidemiological evidence and experimental data."
"This study also is exciting because many of the recent large-scale genomic studies have not discovered new cancer genes with recurrent hot-spot mutations, a pattern strongly indicative of biological importance," said Chin, who also is scientific director of MD Anderson's Institute for Applied Cancer Science.
The six new melanoma genes identified by the team are all significantly mutated and provide potential targets for new treatments.
Those known mutations are important, but don't tell the whole story. Melanoma, the authors note, has higher genetic mutation rates than most other types of solid tumors. The majority are attributable to passenger mutations caused by UV light damage resulting in a DNA alteration called a cytidine (C) to thymidine (T) transition.
Chin together with Levi A. Garraway M.D, Ph.D., associate professor at Dana-Farber Cancer Institute and Harvard Medical School and senior associate member at the Broad Institute, sequenced the exons – active portions of DNA involved in protein synthesis – in 121 melanoma samples paired with normal DNA and found 86,813 coding mutations. The resulting mutation rate was higher than that ever reported in any other tumor type.
Among the most frequently mutated genes, 85 percent of the active coding mutations resulted from C to T transitions caused by UV light exposure.
Statistical approaches to identify driver mutations have often assumed that the baseline mutation rate is uniform across the genome. The abundance of UV-induced passenger mutations that vary in frequency confounds this assumption in melanoma, the researchers report.
"When a gene is found to be repeatedly mutated, we naturally assume that it must be important to the cancer," said Garraway, who is co-senior author with Chin on the study. "However, melanoma can fool us – in that cancer, the very high mutation rate means that many genes can be recurrently mutated purely by chance. We needed a solution to this problem."
To counter this effect, the researchers turned to parts of the genome that don't code for proteins, called introns, and other inactive DNA segments that flank exons. By comparing the frequency of mutations in the inactive segments to the frequency of mutations in the exons, the researchers built a framework for assessing the statistical significance of functional mutations.
Approach identifies six known cancer genes, six new ones
The analysis identified functional mutations in the well-known cancer genes BRAF, NRAS, PTEN, TP53, CDKN2A and MAP2K1.
It also uncovered five new genes, RAC1, PPP6C, STK19, SNX31, and TACC1. Most are associated with molecular pathways involved in cancer but had not been previously recognized as significantly mutated in melanoma. Their presence in the tumor samples ranged from 3 percent to 9 percent.
The sixth new gene tied to melanoma was ARID2, an apparent tumor-suppressor gene possessing a significant number of loss-of-function mutations found in 7% of patient samples.
"Six new melanoma genes have been picked out from thousands of mutated genes," said Eran Hodis, co-lead author who is a computational biologist in the Garraway lab at the Broad Institute and an M.D.-Ph.D. student at Harvard and MIT. "The same approach may bring clarity to genome sequencing studies of other cancers plagued by high passenger mutation rates, for example lung cancer."
UV damage causes 46 percent of driver mutations
The team then cross-referenced their findings with a database of recurrent mutations called COSMIC and gained new insights in the frequency and characteristics of driver mutations, old and newly discovered, in 21 genes.
Out of 262 driver mutations in the 21 genes, 46 percent were caused by UV-induced damage. The well-known tumor-suppressing gene TP53 had the greatest number of UV-caused mutations. Other tumor-suppressors also had loss-of-function mutations and all of the newly identified genes had a high percentage of mutations caused by UV damage.
Most exciting, three of the discovered genes possessed 'hotspot' mutations found in the exact same position in multiple patients providing another line of evidence indicating these mutations contribute to melanoma.
"We have now discovered the third most common hotspot mutation found in melanoma is present in a gene called RAC1, and unlike BRAF and NRAS mutations, this activating mutation is attributable solely to characteristic damage inflicted by sunlight exposure" said Ian R. Watson, Ph.D., co-lead author of the study and postdoctoral fellow in the Chin lab at MD Anderson.
New insights provide opportunity to better understand, treat melanoma
Much work remains following the most comprehensive analysis of the genetics of melanoma, the authors noted. If diagnosed early, melanoma is highly curable, but in its metastatic stage is lethal. Determining the role these mutated genes play in biological processes important for melanoma progression and metastasis provides a new avenue of investigation into the molecular basis of this disease.
With the advent of the BRAF inhibitor vemurafenib, melanoma has emerged as the latest success story for genomics-guided targeted therapy in treatment of patients with metastatic disease. However, melanoma eventually resists this therapy and effective treatment options for patients that do not possess a BRAF (V600) mutation are limited.
Determining whether these newly discovered genes are amenable to targeted therapy, or whether their mutations predict sensitivity to currently available drugs, Chin said, will be an important next step in translating these findings into the clinic.
This work was supported by grants from the National Institutes of Health, including the National Human Genome Research Institute Large Scale Sequencing Program, Grant U54 HG003067, to the Broad Institute; the Melanoma Research Alliance; the University of Texas MD Anderson Cancer Center Melanoma Specialized Program of Research Excellence and Melanoma Informatics, Tissue Resource, and Pathology (Core grant P50 CA93459); MD Anderson's NCI Cancer Center Support Grant (CA-16672); the Canadian Institutes of Health; the Swiss National Science Foundation (PASMP3_134379/1); the G. Harold and Leila Y. Mathers Charitable Foundation; the FWF-Austrian Science Fund (L590-B12); an NIH New Innovator Award (DP2OD002750), NCI (R33CA126674), the Starr Cancer Consortium, National Cancer Institute grant (R01 CA093947), The Cancer Genome Atlas of the NIH (U24 CA143845) the Milestein Innovation Award in Melanoma Research and the Cancer Prevention and Research Institute of Texas.
Laura Sussman | EurekAlert!
A new view of microscopic interactions
01.07.2020 | University of Missouri-Columbia
Microscope allows gentle, continuous imaging of light-sensitive corals
01.07.2020 | Marine Biological Laboratory
Live event – July 1, 2020 - 11:00 to 11:45 (CET)
"Automation in Aerospace Industry @ Fraunhofer IFAM"
The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM l Stade is presenting its forward-looking R&D portfolio for the first time at...
With an X-ray experiment at the European Synchrotron ESRF in Grenoble (France), Empa researchers were able to demonstrate how well their real-time acoustic monitoring of laser weld seams works. With almost 90 percent reliability, they detected the formation of unwanted pores that impair the quality of weld seams. Thanks to a special evaluation method based on artificial intelligence (AI), the detection process is completed in just 70 milliseconds.
Laser welding is a process suitable for joining metals and thermoplastics. It has become particularly well established in highly automated production, for...
A research team from the Max Planck Institute for the Structure of Dynamics (MPSD) and the University of Oxford has managed to drive a prototypical antiferromagnet into a new magnetic state using terahertz frequency light. Their groundbreaking method produced an effect orders of magnitude larger than previously achieved, and on ultrafast time scales. The team’s work has just been published in Nature Physics.
Magnetic materials have been a mainstay in computing technology due to their ability to permanently store information in their magnetic state. Current...
The Venus flytrap (Dionaea muscipula) takes only 100 milliseconds to trap its prey. Once their leaves, which have been transformed into snap traps, have...
NASA-NOAA's Suomi NPP satellite observed a huge Saharan dust plume streaming over the North Atlantic Ocean, beginning on June 13. Satellite data showed the dust had spread over 2,000 miles.
At NASA's Goddard Space Flight Center in Greenbelt, Maryland, Colin Seftor, an atmospheric scientist, created an animation of the dust and aerosols from the...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
01.07.2020 | Physics and Astronomy
01.07.2020 | Power and Electrical Engineering
01.07.2020 | Physics and Astronomy